Tysabri To Go Before Advisory Committee On March 7
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee discussion will include multiple sclerosis therapy’s proposed risk management plan and possible return to market.
You may also be interested in...
Tysabri Relatively Safe For Short-Term Use, NEJM Concludes
No further cases of PML found in two large trials, but editorial urges caution.
Tysabri Relatively Safe For Short-Term Use, NEJM Concludes
No further cases of PML found in two large trials, but editorial urges caution.
FDA Clears Tysabri For Limited Clinical Use
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.